Clinical Validation of the CureMatch Approach
A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle Kurzrock and her clinical use of personalized drug combinations therapies at the Center for Personalized Cancer Therapy at the University of California, San Diego. The advances in personalized cancer treatments appear to lead to better results for cancer patients. Check out the entire […]
New study published in ANTICANCER RESEARCH Journal offers potential proof-of-concept for precision medicine approach to cancer treatment. SAN DIEGO, CA – April 12, 2018: A new in vitro cancer study supports the concept of matched combination therapies as more effective treatment when compared to matched monotherapies or the current standard of care. Among the most […]
New study in The Oncologist supports the use of blood-based tumor DNA (liquid biopsies) in hepatocellular carcinoma (HCC) to facilitate personalized medicine. The CureMatch decision support platform matches personalized drug combinations for liver cancer patients. SAN DIEGO, CA – March 26, 2018: A new cancer study[1] reports that next-generation sequencing of circulating tumor DNA (ctDNA) can provide therapeutically […]
CureMatch’s Tsigelny is a featured author in Briefings in Bioinformatics journal with a review on artificial intelligence’s usefulness in drug combination therapy recommendations. SAN DIEGO, CA – February 12, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch®, is the author of “Artificial intelligence in drug combination therapy” in Briefings in Bioinformatics […]
Molecular study offers insights for possible cure of treatment resistance and new drug possibilities based upon better understanding of the GRP78-Cripto Protein. CureMatch’s Tsigelny published in current Protein Science Journal article. SAN DIEGO, CA – January 31, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch®, is a senior author of “Cripto […]